Targeting Mitochondria for Tomorrow's Health
DRUG SCREENING
The screening and drug discovery strategy at Mitopharma is meticulously designed by utilizing long-lived pharmacology and the latest discovery approaches.
Drug libraries are screened against developed disease models. During drug screening, the generated data is used to detect and identify pharmacological targets that drive mitochondrial dysfunction. Identifying disease targets is one of the major milestones in the drug discovery process.
High Throughput Screening (HTS). Multimode microplate reader with specialized measurement types and capacity of up to 20 (384-well) plates during a single screening. Fast end-point or kinetic read times.
High Content Screening (HCS). Automated HCS systems with the microplate capacity of up to 384-well plates, robotic microplate and liquid handling. Single-cell events can be observed and quantified in live or fixed cells, isolated organs, or small animal models.
Flow Cytometry. At Mitopharma, three flow cytometry systems enable advanced cellular analysis and separation. A high-speed cell sorting system allows isolation of defined cell populations into tubes or microplates for downstream culture and molecular analysis. A high-sensitivity flow cytometer enables detection of sub-micron (down to 100 nm) particles and small biological vesicles. An imaging flow cytometer combines quantitative flow analysis with high-content imaging for detailed single-cell phenotyping. These systems support large-scale population analysis, deep phenotyping and targeted cell isolation.
Quantitative Polymerase Chain Reaction (qPCR). System for detection and quantitation of changes in gene expression and profiling disease models during drug screening.
HPLC-MS/MS. Ion trap system for detection and identification of cellular metabolites, proteins and protein modifications that occur in signaling pathways, as well as ligand-protein and protein-protein interactions. Peptide mapping with High Throughput (HT) sample preparation enables for the parallel analysis and identification of 96 single protein or whole proteome samples.
Cardiac electrophysiology and heart perfusion. Electrophysiology and perfusion systems enable functional assessment of cardiac activity in vivo, ex vivo and in isolated tissue preparations. It supports electrical stimulation, bioamplification, ECG recording and extracellular potential measurements for real-time analysis of cardiac excitability, impulse conduction and pharmacological responses.
Protein/small molecule X-ray crystallography. A high-flux, high-brilliance rotating anode X-ray diffraction system equipped with an image plate detector enables high-resolution diffraction data collection for protein and small-molecule crystals. The system supports de novo structure determination, molecular replacement and structural analysis of protein-ligand interactions. In addition, an automated protein crystallization and crystal imaging system enables high-throughput crystallization screening, optimization and crystal quality assessment.
MALDI-TOF/TOF mass spectrometry. At Mitopharma, two high-performance MALDI-TOF/TOF systems provide fast and accurate mass spectrometric analysis of small molecules, peptides and proteins across a wide mass range. The systems support high-throughput analysis using 384 spot target plates and enable tandem MS/MS for molecular identification and structural characterization. In addition, MALDI imaging of tissue sections can be performed for spatially resolved molecular analysis.